JP2008535494A5 - - Google Patents

Download PDF

Info

Publication number
JP2008535494A5
JP2008535494A5 JP2008505603A JP2008505603A JP2008535494A5 JP 2008535494 A5 JP2008535494 A5 JP 2008535494A5 JP 2008505603 A JP2008505603 A JP 2008505603A JP 2008505603 A JP2008505603 A JP 2008505603A JP 2008535494 A5 JP2008535494 A5 JP 2008535494A5
Authority
JP
Japan
Prior art keywords
cancer
antibody
prlr
expression
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008505603A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535494A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/013160 external-priority patent/WO2006110585A2/en
Publication of JP2008535494A publication Critical patent/JP2008535494A/ja
Publication of JP2008535494A5 publication Critical patent/JP2008535494A5/ja
Pending legal-status Critical Current

Links

JP2008505603A 2005-04-07 2006-04-07 癌関連遺伝子(prlr) Pending JP2008535494A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66986105P 2005-04-07 2005-04-07
PCT/US2006/013160 WO2006110585A2 (en) 2005-04-07 2006-04-07 Cancer-related genes (prlr)

Publications (2)

Publication Number Publication Date
JP2008535494A JP2008535494A (ja) 2008-09-04
JP2008535494A5 true JP2008535494A5 (enExample) 2009-04-02

Family

ID=36809257

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008505600A Pending JP2008535853A (ja) 2005-04-07 2006-04-07 癌関連遺伝子
JP2008505603A Pending JP2008535494A (ja) 2005-04-07 2006-04-07 癌関連遺伝子(prlr)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008505600A Pending JP2008535853A (ja) 2005-04-07 2006-04-07 癌関連遺伝子

Country Status (6)

Country Link
US (1) US20090220495A1 (enExample)
EP (3) EP2083088A3 (enExample)
JP (2) JP2008535853A (enExample)
AU (1) AU2006235258A1 (enExample)
CA (1) CA2604844A1 (enExample)
WO (2) WO2006110581A2 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
DK1974058T3 (da) 2006-01-11 2014-09-01 Genomic Health Inc Genekspressionsmarkører til prognosticering af kolorektal cancer
US8945572B2 (en) 2006-05-12 2015-02-03 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
ES2539042T3 (es) * 2006-06-02 2015-06-25 Glaxosmithkline Biologicals S.A. Procedimiento de identificación de si un paciente será respondedor o no a inmunoterapia
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
CA2661023C (en) * 2006-08-18 2017-08-15 Novartis Ag Prlr-specific antibody and uses thereof
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008118877A2 (en) * 2007-03-23 2008-10-02 The Translational Genomics Research Institute Method of diagnosing, classifying and treating endometrial cancer and precancer
AU2008231575A1 (en) 2007-03-27 2008-10-02 Immunovia Ab Protein signature/markers for the detection of adenocarcinoma
EP2728018B1 (en) * 2007-06-01 2016-11-23 The Regents of The University of California Multigene prognostic assay for lung cancer
ES2694018T3 (es) 2007-07-02 2018-12-17 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el tratamiento y el diagnóstico del cáncer
CA2705486C (en) * 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
US8470607B2 (en) * 2008-03-20 2013-06-25 Morphotek, Inc. Inhibition of angiogenesis
CA2724384A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
EP2373338B1 (en) * 2008-12-03 2017-02-15 The Johns Hopkins University Annexina2 as immunological target
EP2425020A4 (en) 2009-05-01 2016-04-20 Genomic Health Inc GENE EXPRESSION PROFILE GORITHM AND TEST OF PROBABILITY OF REPRODUCTION OF COLORECTAL CANCER AND RESPONSE TO CHEMOTHERAPY
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
JP5858932B2 (ja) 2010-02-04 2016-02-10 モルフォテック, インコーポレイテッド クロロトキシンポリペプチドおよびコンジュゲートならびにその使用
ES2601182T3 (es) 2010-05-11 2017-02-14 Fred Hutchinson Cancer Research Center Variantes de clorotoxina, conjugados y métodos para su utilización
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
GB201103726D0 (en) 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2012136519A1 (en) 2011-04-06 2012-10-11 Bayer Pharma Aktiengesellschaft Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer
EP2530089A1 (en) 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
WO2013012747A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013044164A1 (en) * 2011-09-21 2013-03-28 The Regents Of The University Of California Methods to treat and/or prevent relapse in notch1-driven malignancies
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
BR112014019741A2 (pt) * 2012-02-11 2020-12-22 Genentech, Inc Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US20150079003A1 (en) * 2012-05-01 2015-03-19 Univeristy of Washington through its Center for Commreicalization Methods and Compositions for Cancer Diagnosis
KR102082098B1 (ko) * 2012-05-11 2020-02-26 국립연구개발법인 고쿠리츠간켄큐센터 신장 세포암의 예후 예측방법
CN104854132A (zh) 2012-07-13 2015-08-19 昂考梅德药品有限公司 Rspo3结合剂及其用途
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
SG11201504600UA (en) 2012-12-10 2015-07-30 Hutchinson Fred Cancer Res Methods for screening
TWI582239B (zh) * 2013-03-11 2017-05-11 諾華公司 與wnt抑制劑相關之標記
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2015008686A (ja) * 2013-06-28 2015-01-19 三菱レイヨン株式会社 肝臓細胞又はその前駆細胞に由来する細胞の状態を評価する方法、並びに、その方法に用いるプローブ又はプローブセット及びマイクロアレイ
US9567641B2 (en) 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
US10323285B2 (en) 2013-09-09 2019-06-18 Nantomics, Llc Proteomics analysis and discovery through DNA and RNA sequencing, systems and methods
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
US10344073B2 (en) 2014-01-09 2019-07-09 Hadasit Medical Research Services And Development Ltd. Cell compositions and methods for cancer therapy
US9994912B2 (en) 2014-07-03 2018-06-12 Abbott Molecular Inc. Materials and methods for assessing progression of prostate cancer
WO2016044295A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
AU2018315434A1 (en) 2017-08-10 2020-04-02 The Institute Of Cancer Research: Royal Cancer Hospital Materials and methods for stratifying and treating cancers
WO2019112489A1 (en) * 2017-12-05 2019-06-13 Limited Liability Company "Gero" Methods and agents for treatment of aging and aging related conditions and diseases
JP7458318B2 (ja) 2018-02-12 2024-03-29 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 癌治療のためのslamf6スプライスバリアントの調節
KR101890392B1 (ko) * 2018-05-28 2018-08-21 의료법인 성광의료재단 Wnt3a를 포함하는 난소암의 진단을 위한 마커 및 조성물
KR20200115883A (ko) * 2019-03-28 2020-10-08 황인후 테트라스파닌-2 억제제를 유효성분으로 포함하는 췌장암 예방, 개선 또는 치료용 조성물
KR102169901B1 (ko) * 2019-05-17 2020-10-26 연세대학교 산학협력단 Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
WO2020235943A1 (ko) * 2019-05-21 2020-11-26 (주)아큐레시스바이오 암의 진단용 조성물
IL267614A (en) * 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
TW202135861A (zh) * 2019-12-25 2021-10-01 中國大陸商上海尋百會生物科技有限公司 藉由靶向igsf8以治療自體免疫疾病及癌症之組合物及方法
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN114487418A (zh) 2022-02-17 2022-05-13 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) TGFb RIII蛋白作为胃癌血清生物标志物的应用
WO2026028902A1 (ja) * 2024-08-01 2026-02-05 学校法人慈恵大学 診断薬、膵癌診断キット、検出方法、マーカー、抗膵癌剤、及び膵癌治療用組成物
WO2026071613A1 (ko) * 2024-09-25 2026-04-02 한국과학기술원 높은 악성도의 위암 아형 진단용 바이오마커, 및 이를 이용한 예후 예측 방법

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4956453A (en) 1985-12-06 1990-09-11 Cetus Corporation Anti-human ovarian cancer immunotoxins and methods of use thereof
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5359100A (en) 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
WO1990010448A2 (en) 1989-03-07 1990-09-20 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
WO1992002526A1 (en) 1990-07-27 1992-02-20 Chiron Corporation Large comb-type branched polynucleotides
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE190354T1 (de) 1990-12-20 2000-03-15 Arch Dev Corp The University O Kontrolle der genexpression durch ionisierende strahlung
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
JPH07503372A (ja) 1992-01-23 1995-04-13 バイカル・インコーポレイテッド 生体外遺伝子導入
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
AU4115693A (en) 1992-04-24 1993-11-29 Sri International In vivo homologous sequence targeting in eukaryotic cells
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM.
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
AU6818094A (en) 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
WO1995007994A2 (en) 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
HUT75162A (en) 1993-11-16 1997-04-28 Depotech Corp Vesicles with controlled release of actives
US5681697A (en) 1993-12-08 1997-10-28 Chiron Corporation Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
EP0877752B1 (en) 1996-01-23 2003-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and rna molecules
DE69739286D1 (de) 1996-05-06 2009-04-16 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US6406840B1 (en) 1999-12-17 2002-06-18 Biomosaic Systems, Inc. Cell arrays and the uses thereof
DE10019058A1 (de) * 2000-04-06 2001-12-20 Epigenomics Ag Detektion von Variationen des DNA-Methylierungsprofils
WO2002050098A2 (en) * 2000-12-18 2002-06-27 Genaissance Pharmaceuticals, Inc. Haplotypes of the prlr gene
US7645441B2 (en) * 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2003008583A2 (en) * 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7713526B2 (en) * 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
JP2005532036A (ja) * 2002-01-09 2005-10-27 理化学研究所 癌プロフィール
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2003104275A2 (en) * 2002-06-06 2003-12-18 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
WO2004016317A1 (en) * 2002-08-14 2004-02-26 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
EP1651162B1 (en) 2003-05-20 2015-10-21 ImmunoGen, Inc. Improved cytotoxic agents comprising new maytansinoids
WO2004105573A2 (en) * 2003-05-21 2004-12-09 The Wistar Institute Of Anatomy And Biology Method of diagnosis of cancer based on gene expression profiles in cells
JP2007506442A (ja) * 2003-05-30 2007-03-22 ゲノミック ヘルス, インコーポレイテッド Egfr阻害薬への応答に関する遺伝子発現マーカー
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP2006526998A (ja) * 2003-06-12 2006-11-30 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー 胃癌および転移性胃癌診断キット
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
JP2005073548A (ja) * 2003-08-29 2005-03-24 National Cancer Center-Japan 卵巣明細胞腺癌の検査、治療、および治療薬のスクリーニングのための、HNF−1βの利用
WO2005028675A2 (en) * 2003-09-24 2005-03-31 Oncotherapy Science, Inc. Methods for detecting, diagnosing and treating hepatocellular carcinomas (hcc)
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
WO2006034328A2 (en) * 2004-09-21 2006-03-30 Rhode Island Hospital, A Lifespan-Partner Wnt proteins and detection and treatment of cancer

Similar Documents

Publication Publication Date Title
KR102252332B1 (ko) 암 전이의 예후 및 치료 방법
US20230381209A1 (en) Therapeutic treatment of breast cancer based on c-maf status
JP5926487B2 (ja) ErbB療法に耐性である癌を治療するための方法
KR102226219B1 (ko) 폐암 전이의 진단, 예후 및 치료 방법
DK3055429T3 (en) Procedure for the prognosis and treatment of metastatic bone cancer resulting from breast cancer
Remmelink et al. Identification by means of cDNA microarray analyses of gene expression modifications in squamous non-small cell lung cancers as compared to normal bronchial epithelial tissue
KR20150122731A (ko) 암 전이의 예후 및 치료 방법
KR20200104298A (ko) c-MAF 상태에 기반한 유방암의 요법 치료
Liu et al. Vascular endothelial growth factor B coordinates metastasis of non-small cell lung cancer
TWI567391B (zh) 辨識早期肺腺癌病患之次群組之生物標記
WO2008057329A2 (en) Method for detecting and controlling cancer
JP2014501918A (ja) ベバシズマブ併用療法のためのマーカーとしてのagtr1
ITCH20120008A1 (it) Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate
CN102947446A (zh) 肺腺癌的预后预测方法、肺腺癌的检测试剂盒以及用于治疗肺腺癌的医药组合物
JP2008535491A5 (enExample)
CN117129690B (zh) Grhl1在her2-乳腺癌诊断及预后评估中的应用
KR102897399B1 (ko) 유방암 진단을 위한 신규 바이오마커
WO2011129427A9 (ja) 癌の診断剤および治療剤
JP2008535855A5 (enExample)
JP2009523004A5 (enExample)
CN111440870B (zh) CircZCCHC11及其翻译的肽段在肿瘤生长和转移预测、预后评估和治疗中的应用
JP2008535854A5 (enExample)
WO2017012944A1 (en) Method for individualized cancer therapy
JP2007077155A5 (enExample)
Shaker et al. Tenascin-C as a new marker for the diagnosis and treatment monitoring of breast cancer.